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Abstract: Fucoidan is a brown algae-derived polysaccharide having several biomedical applications.
This study simultaneously compares the anti-cancer activities of crude fucoidans from Fucus vesiculosus
and Sargassum filipendula, and effects of low (LMW, 10–50 kDa), medium (MMW, 50–100 kDa) and
high (HMW, >100 kDa) molecular weight fractions of S. filipendula fucoidan against osteosarcoma
cells. Glucose, fucose and acid levels were lower and sulphation was higher in F. vesiculosus crude
fucoidan compared to S. filipendula crude fucoidan. MMW had the highest levels of sugars, acids and
sulphation among molecular weight fractions. There was a dose-dependent drop in focal adhesion
formation and proliferation of cells for all fucoidan-types, but F. vesiculosus fucoidan and HMW had the
strongest effects. G1-phase arrest was induced by F. vesiculosus fucoidan, MMW and HMW, however
F. vesiculosus fucoidan treatment also caused accumulation in the sub-G1-phase. Mitochondrial damage
occurred for all fucoidan-types, however F. vesiculosus fucoidan led to mitochondrial fragmentation.
Annexin V/PI, TUNEL and cytochrome c staining confirmed stress-induced apoptosis-like cell death
for F. vesiculosus fucoidan and features of stress-induced necrosis-like cell death for S. filipendula
fucoidans. There was also variation in penetrability of different fucoidans inside the cell. These
differences in anti-cancer activity of fucoidans are applicable for osteosarcoma treatment.
Keywords: apoptosis; necrosis; brown algae; mitochondria; MG63 cells; fucoidan; transmission
electron microscopy; molecular weight fraction; crude extract; cell cycle
1. Introduction
Fucoidan is a class of sulphated and fucose-rich polysaccharides usually derived from the fibrillar
cell walls and intracellular spaces of brown algae. First isolated by Kylin in 1913 [1], fucoidan has
been demonstrated to have several biological properties ranging from anti-cancer, anticoagulant,
and antithrombotic, antiviral, immunomodulatory and antioxidant [2]. Several factors can affect the
structure of fucoidan, such as the species of seaweed from which it is extracted [2,3], habitat, season of
harvest [4] and extraction method [5]. These can alter fucoidan’s molecular weight, monosaccharide
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composition, position of sulphate ester group, branching pattern and level of sulphation, ultimately
affecting its bioactivity [6].
Fucoidan from Fucus vesiculosus has been the most widely studied. Other than this, fucoidans
from Cladosiphon novae-caledoniae [7], Cladosiphon okamuranus [8], Sargassum filipendula [9], Undaria
pinnatifida [10], Fucus evanescens [11], Sargassum polycystum [12], Saccharina japonica [13], Himantothallus
grandifolius [14] and Sargassum muticum [15] (reviewed in References [16–19]) have also been investigated.
However, fucoidan from Sargassum filipendula has not previously been investigated or exploited for
biomedical applications. For the first time, this study explores fucoidan from S. filipendula, growing
abundantly across the coastal regions of Colombia, for its effects on cancer cells. Identification of a
medical benefit for this invasive species may have economic and environmental benefits for the region.
Molecular weight fractions of fucoidans have also been shown to affect the bioactivity of fucoidan.
Cho et al. [20] compared native forms of two molecular weight (MW) fractions of fucoidan extracts
in the ranges of 5–30 kDa and >30 kDa from U. pinnatifida, and found that there was almost two
times stronger dose-dependent (for doses 200 to 800 µg/mL) antiproliferative activity of 5–30 kDa MW
compared to the >30 kDa fraction, against the stomach cancer cell line AGS. Álvarez-viñas et al. [15]
recently compared <5, 5–10, 10–30, 30–50, 50–100 and >100 kDa of fucoidan extracts from S. muticum for
their anti-cancer activity against cervical cancer (HeLa 229), ovarian cancer (A2780), hepatocarcinoma
(HepG2) and kidney (LLC-PK1) cells. The results showed that overall, HeLa 229 and A2780 cells were
more strongly inhibited than HepG2 and LLC-PK1 cells, and even though the maximal sulphate content
was found in the >100 kDa fraction, the cytotoxic activity was maximal for the 5–30 kDa fraction.
Anti-tumor or anti-cancer activities of different fucoidans havebeen widely investigated for
breast cancer [7,21–24], colon/colorectal cancer [3,25–28], liver cancer [13,29], lymphoma [8] and
lung cancer [11,30]. However, the effect of fucoidan on osteosarcoma has only recently been
investigated [31–33].
Osteosarcoma is the most common type of bone cancer occurring in the proximal humerus
(usually around the knee), distal femur and proximal tibia of younger children (more than 5 years of
age), teenagers (it is the third most common cancer in adolescence) and older adults [34]. Currently,
neoadjuvant and adjuvant chemotherapies, before and after surgery, are used for treating osteosarcoma.
Up to 30% of patients with high-grade osteosarcoma may develop local or distal recurrence after
therapy and this cancer may metastasise to the lungs. The prognosis is poor with deteriorating quality
of life. The 5-year survival rate for osteosarcoma is 60%–70%. Recently, it has been highlighted that
cell proliferation, apoptosis, adhesion, invasion and metastasis represent potential biological targets
for treating osteosarcoma [35], and that one of the most potent natural drugs for this application
may be fucoidan. Fucoidanhas been shown to inhibit cancer cells by inducing apoptosis via several
mechanisms [21,22,24,29,33,36–41], such as inhibition of cell proliferation and invasion by targeting cell
cycle proteins and the PI3K-Akt-mTOR pathway [42], inhibition of Vascular Endothelial Growth Factor
and Matrix Metalloproteinases [30], enhancing ubiquitin-dependent TGFβ receptor degradation [23,43]
and regulating the miR-29c/ADAM12 and miR-17-5p/PTEN axes [44].
This study simultaneously compares the anti-cancer activities of crude fucoidans from two brown
seaweed species F. vesiculosus and S. filipendula, and the effects of low-, medium- and high-MW (LMW,
MMW and HMW) fractions of fucoidan derived from S. filipendula against MG63 osteosarcoma cells.
Using size-fractionated fucoidan, we also demonstrate that as the molecular weight of fucoidan
increases, the anti-cancer activity of fucoidan also increases.
2. Results
2.1. Natural Sugars, Sulphation and Acid Contents in Fucoidan
Comparison of neutral sugars, sulphation and acid contents in different fucoidans indicated that
the lowest levels of neutral sugars and acid were present with the highest levels of sulphation (1.5 to
2 times more) in the case of crude extract from F. vesiculosus compared to all other fucoidans (Table 1).
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Table 1. Neutral sugars and uronic acid contents expressed as % of initial total mass and % of sulphation
for the different fucoidans under study. Mean ± standard deviation (SD).
Fucoidan-Type
Neutral Sugars (%)
Uronic Acids (%) Sulfation (%)
Glucose Fucose
F. vesiculosus Crude 7.88 ± 0.04 56.57 ± 0.01 8.28 ± 0.01 33.92 ± 0.09
S. filipendula Crude 11.18 ± 0.01 79.48 ± 0.02 11.83 ± 0.01 16.52 ± 0.02
S. filipendula LMW 10.95 ± 0.01 76.69 ± 0.01 10.00 ± 0.04 15.05 ± 0.01
S. filipendula MMW 11.87 ± 0.01 82.31 ± 0.01 12.66 ± 0.01 25.99 ± 0.01
S. filipendula HMW 10.95 ± 0.02 70.28 ± 0.01 12.26 ± 0.01 20.13 ± 0.03
2.2. Effect of Fucoidan on MG63 Cell Attachment and Morphology
To assess attachment of MG63 cells in medium supplemented with fucoidans, cells were seeded
in media containing a range of doses of different fucoidan types. The results (Figure 1A,B) showed
a dose-dependent drop in MG63 metabolic activity and DNA content for all fucoidan types with
differences in severity based on fucoidan type. Comparison of the two crude extracts showed a more
severe reduction in the case of F. vesiculosus for doses up to 10 µg/mL. At a higher dose of 100 µg/mL,
there seemed to be similar DNA content in both conditions but more cell metabolic activity in MG63s
seeded in the presence of fucoidan from F. vesiculosus, which suggested that mitochondria in the latter
cells were more active.
Comparison of different molecular weight fractions of fucoidan from S. filipendula showed that
higher molecular weight led to lower cell attachment, as measured by metabolic activity or DNA
content. These trends were visible up to the 10 µg/mL dose, and by 100 µg/mL, cells treated with
MMW or HMW had similar cell numbers which were significantly lower than LMW-treated cells.
Immunostaining for actin and vinculin (Figure 1C) showed that in control conditions, MG63 cells
tended to have a flat and angular morphology with vinculin being highly expressed at the pointed
edges of the cells. In the presence of 0.5 µg/mL of fucoidan from F. vesiculosus, MG63 cells appeared to be
either more rounded or more elongated due to the accumulation of actin in the cell cortex and vinculin
staining was lost. On the other hand, in the presence of 0.5 µg/mL of crude fucoidan from S. filipendula,
the cells seemed to retain their typical morphology and vinculin expression. When 0.5 µg/mL LMW,
MMW and HMW fractions were compared, only MMW and HMW fractions from S. filipendula caused
irregular and rounded cells. Finally, at a dose of 100 µg/mL, MG63 cells always exhibited a rounded
morphology with no typical vinculin expression, irrespective of the type of fucoidan supplemented.
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Figure 1: Effect of different fucoidans on MG63 cell attachment. Mean ± S.D. of A) metabolic activity 
and B) DNA content after 24 h of seeding  in  the presence of  fucoidan  (n = 6). C) Max  intensity z‐
projections for DAPI (blue), Actin (Texas Red) and Vinculin (FITC) stained cells with overlays, after 
24 h of seeding in presence of fucoidan. Scale bars, 25 μm. * p < 0.05, # p < 0.05 relative to respective 
vehicle controls. 
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Figure 1. Effect of different fucoidans on G63 cell attach ent. Mean ± SD of (A) metabolic activity
and (B) DNA content after 24 h of seeding in the presence of fucoidan (n = 6). (C) Max intensity
z-projections for DAPI (blue)-, Actin (Texas Red)- and Vinculin (FITC)-stained cells with overlays, after
24 h of seeding in presence of fucoidan. Scale bars, 25 µm. * p < 0.05, # p < 0.05 relative to respective
vehicle controls.
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We further calculated the percentage of cells that rounded after 24 h of seeding in the presence
of different types of fucoidan. The results (Supplementary Figure S1) suggested that at a 0.5 µg/mL
dose, there was a similar percentage of rounded cells in the case of both crude fucoidans. However,
a comparison of LMW, MMW and HMW fractions from S. filipendula showed that as the molecular
weight fraction increased, the percentage of rounded cells also increased. Altogether, these results
suggest that the effect of fucoidan on MG63 attachment is dependent upon the species it is derived
from and the molecular fraction of fucoidan used.
2.3. Effect of Fucoidan on MG63 Cell Growth and Mitochondrial Activity
In a preliminary experiment, cells were seeded and the next day, treatment with different doses
of crude fucoidan from F. vesiculosus was started (Supplementary Figure S2). After 24 h of exposure,
DNA content and cell metabolic activity measurements were performed. The results showed that after
only one day, the cells were unable to survive at doses higher than 100 µg/mL. The cells were noted to
round up and fragment into smaller debris. Though the DNA measurements showed a lower mean
value for 100 µg/mL compared to control, this difference was not statistically significant, and some cell
debris was also visible at this dose. Hence, for further investigations, concentrations were restricted to
100 µg/mL of fucoidan or less.
For comparison of different types of fucoidan, experiments were extended up to three days of
culture and cells were grown in media supplemented with 0 to 100 µg/mL of different fucoidans.
Cell metabolic activity measurements (Figure 2A) also showed a dose-dependent effect on metabolic
activity after treatment with all types of fucoidan, with the lowest activity relative to controls for
cells treated with 100 µg/mL of crude fucoidan from F. vesiculosus. Additionally, there seemed to be a
molecular weight-dependent effect of fucoidan from S. filipendula on cell metabolic activity. At 1, 10 and
100 µg/mL, there was higher metabolic activity for cells treated with crude and/or LMW fucoidan
extracts, followed by the MMW fraction and metabolic activity was lowest in the case of cells treated
with the HMW fraction.
DNA content measurement confirmed the metabolic activity data (Figure 2B). There was a
dose-dependent effect on cell numbers after treatment with all types of fucoidan; however, the strongest
effect was seen in the case of crude fucoidan from F. vesiculosus. Additionally, by 100 µg/mL, there was
no significant difference between cells under any of the S. filipendula fucoidans treatment.
Giemsa staining was performed to study the cell morphology after three days of exposure to
fucoidan. Cells in control conditions had clearly defined nuclei with flat morphology, indicative of
good cell health (Figure 2C), whereas cells exposed to 0.5, 10 and 100 µg/mL of crude fucoidan from
F. vesiculosus had some cells with dark and condensed nuclei with debris surrounding them, suggestive
of cell death. In the case of different fucoidan from S. filipendula, a dose-dependent effect was seen,
and at 100 µg/mL, there was evidence of cell death.
Mar. Drugs 2020, 18, 104 6 of 29
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2.4. Ultrastructure Examination of MG63 Cells Treated with Fucoidan
To further understand the effect of fucoidan on cell ultrastructure and organelle organisation,
TEM was performed for cells treated with fucoidan for three days (Figure 3). In control (0 µg/mL) MG63
cells, the cytosol near the nucleus was grainy and seemed to consist of cell organelles, which were close
to the nucleus rather than dispersed through the cytosol. Higher magnification electron micrographs
showed that mitochondria in normal cells had regular structure with clear cristae formation and
an extensive endoplasmic reticulum (ER) network in the cytosol. The maximum size of vesicles in
the cytoplasm was observed to be around 1 µm by visual inspection. For MG63 cells treated with
100 µg/mL of crude fucoidan from F. vesiculosus, cells that were intact had visible signs of blebbing
in the cell membrane, extensive ER-like swelling, signs of autophagosome formation, chromatin
condensation and marginalisation. Some other cells had broken cell or nuclear membranes and their
cytoplasm was less granular or dense. The granularity of the nucleoplasm also became less in cells that
appeared to be dying. The mitochondria in all these cells were swollen, very dense and seemed to be
disintegrating and losing their cristae structure, which appeared like a dense matrix within the cytosol.
Moreover, their distribution was visibly less in the cytosol as compared to mitochondria in the control.
There were also signs of cell debris and fragments, possibly of these ruptured cells, within the same
sample. When these cells were compared to the cells treated with crude fucoidan from S. filipendula,
again there seemed to be signs of significant cell death but with some differences. The occurrence of
blebs in the cells was less common and there were more cells in the sample with lost cell membrane
integrity or rupturing. These cells, as well as some other less damaged cells, seem to have visible
ER-like swelling and less dense cytoplasm. The mitochondria were also very dense and swollen and
their cristae structure seemed to be collapsing into a dense matrix within the mitochondria. However,
other mitochondria had a visible cristae structure that was not fully disintegrated but lacked orientation
and were marginalised towards the edges of the mitochondrial membrane, leading to development
of gaps inside the mitochondria. The nucleoplasm was less granular and there were also regions of
condensed filaments, which may be cytoskeletal actin-filaments in the cytosol. There were also signs of
autophagosomes in a few cells, although this was not common. These results indicated that while both
crude fucoidans at 100 µg/mL were leading to cell death, their mechanism of action may be different.
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Figure 3. TEM of MG63 cells treated with 100 µg/mL of crude fucoidan from F. vesiculosus or S. filipendula (at least 10–15 cells analysed per condition). Red
arrows—mitochondria, orange arrows—vesicles or vacuoles, orange dashed line—perinuclear region rich in organelles in control cells, N—nucleus, B—blebbing
in the cell membrane, D—cellular debris, yellow arrow heads—chromatin condensation and marginalisation, green arrow heads—membrane nicks, yellow
arrows—endoplasmic reticulum at higher magnification.
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TEM was also carried out to study the effects of 100 µg/mL of LMW, MMW and HMW fucoidans
from S. filipendula on MG63 cells (Figure 4). For all three fucoidan types, there were a number of
cells with condensation of the actin-like filaments in the cytosol. However, it was seen more for
MMW- and HMW-treated samples. The mitochondria were again dense and seemed to have swollen
cristae structures, which were disintegrating in more damaged cells. There was also the presence
of autophagocytosis in a few treated cells, characterised by highly dense granulated structures or
vesicles containing cellular material in the cytoplasm. Moreover, swelling in the cells with ruptured
cell membranes and leaking cytoplasm were also a common feature for all fucoidan types. One of the
typical features of the intact or dying cells treated with MMW or HMW was the presence of dark spots
in the chromatin material in the nucleus, suggestive of fragmented nucleolus or upregulated ribosomal
biosynthesis. There were also some cells with blebs in the MMW- and HMW-treated samples, however,
this was not a common feature. Altogether, these results confirm that the MMW and HMW fractions of
the crude fucoidan from S. filipendula were more toxic than the LMW fraction.
2.5. Effect of Fucoidan on Cell Cycle
PI staining was performed to investigate the effect of fucoidan on the MG63 cell cycle. After three
days of treatment with crude fucoidan from F. vesiculosus, there were nearly 70%–72.5%, 8.4%–8.6%,
16.5%–15.4% and 3%–3.8% cells in the G1, S, G2 and sub-G1 phases respectively, for doses up to
0.5 µg/mL (Figure 5). However, at 100 µg/mL, these values changed to 36.2%, 11.7%, 28% and
23.5%, respectively. The dramatic changes in population distribution indicated cell cycle arrest in
G1 phase that inhibited the cells from entering the S phase and accumulation of cells in the sub-G1
population. In contrast, treatment with 100 µg/mL of crude or molecular weight fractions of fucoidan
from S. filipendula showed no significant variation in sub-G1 phase compared to lower doses. However,
there seemed to be fewer cells present in S and G2 phase and more cells in G1 phase at 100 µg/mL of
MMW and HMW fractions compared to lower concentrations, again indicative of arrested cells in G1
phase of cell cycle [45]. A confirmatory cell cycle analysis on Day 2 of treatment with S. filipendula
fucoidans was also performed to validate these results (Supplementary Figure S3).
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Figure 4. TEM of G63 cells treated with 100 µg/mL of LMW, MMW and HMW fractions of fucoidan
from S. filipendula (at least 10 cells were analysed per condition). Different features of structural
damage are indicated. Red arrows—mitochondria, N—nucleus, A—condensed actin filaments,
ER—endoplasmic reticulum, Au—autophagosomes, B—blebbing, CM—damaged cell membrane.
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cells in G1 phase in after treatment with 100 μg/ml of crude fucoidan from F. vesiculosus relative to other conditions. There were also fewer cells in S and G2 phases and 
more cells in G1 phase after treatment with 100 μg/ml of MMW or HMW (blue arrows) derived from S. filipendula compared to untreated condition or lower doses of same 
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C o
u n
t s
Blue 610/20-A
0 µg/ml
0.5 µg/ml 
100 µg/ml
0 µg/ml
Crude 0.5 µg/ml
Crude 100 µg/ml
LMW 0.5 µg/ml
LMW 100 µg/ml
MMW 0.5 µg/ml
MMW 100 µg/ml
HMW 0.5 µg/ml
HMW 100 µg/ml
(x 1000)
3% 15.4%8.4%72.5%
3.8% 16.5%8.6%70%
23.5% 28%11.7%36.2%
2.6% 16.2%9.7%70.6%
2.2% 17%10.9%69%
2.3% 15%9%72.8%
3.4% 15.6%9.7%70.3%
2.7% 17.7%9.1%69.4%
3.1% 19.3%10.3%66.2%
3% 15.5%8.7%72% 3.6% 13.8%7%74.7%
3.4% 18.1%10.7%67.1%
F. vesiculosus S. filipendula
Figure 5. Cell cycle analysis of MG63 cells after 3 days treatment with different fucoidans at 0, 0.5 and 100 µg/mL. Nearly 10,000 single cell events were measured after
staining with PI (n = 1). Populations were split into sub-G1, G1, S and G2 phases. Notice the presence of more cells in sub G1, S and G2 phases (green arrows) and
fewer cells in G1 phase in after treatment with 100 µg/mL of crude fucoidan from F. vesiculosus relative to other conditions. There were also fewer cells in S and G2
phases and more cells in G1 phase after treatment with 100 µg/mL of MMW or HMW (blue arrows) derived from S. filipendula compared to untreated condition or
lower doses of same fucoidans.
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2.6. Annexin V/PI Staining
To investigate if the cell death as a result of fucoidans treatment was due to apoptosis or necrosis,
cells were seeded and treated with different fucoidans for three days. Crude fucoidan from F. vesiculosus
at 100 µg/mL led to significantly fewer viable cells and more apoptotic or dead cells after treatment
compared to respective vehicle control (0 µg/mL) (Figure 6, Supplementary Figure S4). This effect
was dose-dependent. There were also reduced numbers of viable cells in samples treated with
crude fucoidan from S. filipendula compared to the respective vehicle control (0 µg/mL) or other
molecular weight fractions of fucoidan. Early apoptosis was more pronounced in crude fucoidan
from F. vesiculosus and late apoptosis was more common in crude fucoidan from S. filipendula at the
100 µg/mL dose, indicative of differences in the mechanism of action of both fucoidans. Comparison of
molecular weight fractions showed that there appeared to be more early and late apoptotic cells after
treatment with 100 µg/mL HMW compared to 100 µg/mL LMW or MMW, though this effect was not
statistically significant. There were more dead cells after treatment with MMW compared to LMW-
and HMW-treated cells at the same dose. These results indicate that both MMW and HMW fractions
were more toxic to cells and led to cell death, mostly via necrosis with some evidence of apoptosis.
2.7. Assessment of DNA Fragmentation in MG63 Cells after Fucoidan Treatment
Nuclear chromatin fragmentation is the hallmark of late-stage apoptosis, and in order to
assess apoptosis-induced DNA fragmentation, a TUNEL assay was performed. There was a clear
dose-dependent increase in cells positive for BrdU (TRITC-labelled) expression from 4% (for 0 µg/mL)
to 86% (for 100 µg/mL) after treatment with crude fucoidan from F. vesiculosus (Figure 7). On the
other hand, the increase was only from 3% (for 0 µg/mL) to 11% (for 100 µg/mL) after treatment with
crude fucoidan from S. filipendula. Furthermore, when molecular weight fractions of fucoidan from
S. filipendula were assessed, the results showed a very subtle increase in BrdU-expressing cells from
2%–3% (for 0.5 µg/mL) to 5% (for 100 µg/mL) after treatment with LMW and MMW. However, there was
a four-fold increase after treatment with HMW from 4% (for 0.5 µg/mL) to 16% (for 100 µg/mL). These
results clearly indicate that there can be different actions of fucoidan on chromatin material depending
upon the species of algae as well as the molecular weight fraction of fucoidan used.
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Figure 6. Annexin V/PI staining of MG63 cells under the effect of different fucoidans after 3 days
of treatment. Representative population splits are shown. Nearly 10,000 single cell events were
measured after staining live cells with Annexin V/PI and populations were split into viable (green
events), early apoptotic (blue events), late apoptotic (pink events) and dead cells (re e e ts).
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Figure 7: TUNEL assay for MG63 cells after 3 days treatment with different fucoidans. Nearly 6,000 
single cell events were measured and populations were split into TRITC‐ (blue events, BrdU‐) and 
TRITC+  (red  events, BrdU+) using  assay  controls  (n  =  1). Notice  the dose dependent  increase  in 
TRITC+ cells after treatment with crude fucoidan from F. vesiculosus and HMW from S. filipendula. 
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2.8. Effect of Fucoidan on Mitochondrial Health
To investigate if mitochondrial integrity was affected by fucoidan, live MG63 cells were stained
with JC-1 after three days of fucoidan treatment. The results (Figure 8A,B) showed higher green-to-red
ratios, and depolarization of mitochondrial membrane for all types of S. filipendula fucoidans at the
100 µg/mL dose, which was particularly high in the case of HMW. Interestingly, the lined features
of J-aggregates (red channel) in cells treated with 100 µg/mL crude fucoidan from F. vesiculosus were
reduced to small dots, indicative of mitochondrial fragmentation.
We further investigated the expression of Cyt C in MG63 after fucoidan treatment at the same time
point (Figure 8C,D). There appeared to be the highest Cyt C expression across the cytoplasm of the
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entire cells after treatment with 100 µg/mL of crude fucoidan from F. vesiculosus. However, this increase
was not seen in any of the other treated conditions and the expression was restricted to the perinuclear
region. Collectively, the above results clearly indicate that fucoidan acts differently on mitochondria
depending upon the species of algae and the molecular weight fraction.
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Figure 8: Assessment of mitochondria in MG63 cells after 3 days treatment with different fucoidans. 
(A) Mitochondrial membrane potential changes measured using JC‐1 staining (at least 10 cells were 
analysed per condition). (B) Representative images of live cells taken under 525 nm (green) and 647 
nm (red) channels with overlays. Scale bars‐ 25 μm. (C) Mean ± S.D. of Cyt c signal to DAPI signal (n 
= 3  fields of view).  (D) Representative overlay  images of cells stained with Cyt c  (Red) and DAPI 
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Figure 8. Assessment of mitochondria in MG63 cells after 3 days treatment with different fucoidans.
(A) Mitochondrial membrane potential changes measured using JC-1 staining (at least 10 cells were
analysed per condition). (B) Representative images of live cells taken under 525 nm (green) and 647 nm
(red) channels with overlays. Scale bars—25 µm. (C) Mean ± SD of Cyt C signal to DAPI signal (n = 3
fields of view). (D) Representative overlay images of cells stained with Cyt C (Red) and DAPI (blue).
Arrows—localization of Cyt c in perinuclear regions. Scale bar—10 µm. * p < 0.05, # p < 0.05 relative to
respective vehicle controls.
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2.9. Localization of Fucoidan in MG63 Cells
To study the interaction of different fucoidans with MG63 cells, immunostaining for fucoidan was
performed for cells treated for three days (Figure 9). There seemed to be a large amount of penetration
of crude fucoidan from S. filipendula inside the cells, covering the entire cytosol. On the other hand,
crude fucoidan from F. vesiculosus was only seen as clumps either near the edges of the cells or inside
the cells, exhibiting limited penetration.
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Figure 9: Penetration of different fucoidans in MG63 cells after 3 days of treatment. Max intensity z‐
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shown. At  least 3  fields of view were analysed per condition. There are differences  in patterns of 
staining  for different crude  fucoidan  types  (white arrows). Yellow arrows  ‐ condensed chromatin. 
Scale bars‐ 25 μm. 
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Figure 9. Penetration of iff r t f coidans in MG63 cells after 3 days of treatment. Max intensity
z-projections for DAPI (blue)-, actin (green)- and fucoidan (red)-stained cells with overlay images
are shown. At least 3 fields of vie were analysed per condition. There are differences in patterns
of staining for different crude fucoidan types (white arrows). Yellow arrows—condensed chromatin.
Scale bars—25 µm.
3. Discussion
Fucoidans from various different species of brown seaweed have been studied for anti-cancer
applications. While most of the research revolves around more common forms of cancer, such as
breast and colon cancer [6], use of fucoidan against osteosarcoma has recently been a keen area of
interest [31–33], as even though it is a relatively less common cancer, the implications can be severe [34].
For the first time, here, we investigated the variable effects of crude fucoidan derived from two
different species of brown algae, namely, F. vesiculosus (commercial source) and S. filipendula (derived
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from Colombian coast), and further evaluated the effect of different molecular weight fractions from
10–50 kDa (LMW), 50–100 kDa (MMW) and >100 kDa (HMW) fractions of fucoidan from S. filipendula
on MG63 human osteosarcoma cells.
3.1. Fucoidan Causes G1 Phase Cell Cycle Arrest in MG63 Cells
A wide variety of previous studies reported cell cycle arrest in G1 or G2/M phase after fucoidan
treatment [22,36,46]. A previous study showed that fucoidan from F. vesiculosus caused G0/G1 arrest
of HT29 colon cancer cells after 24 h of treatment and it was dose-dependent (0, 50 and 100 µg/mL).
This was associated with upregulation of p21WAF1 expression and suppression of cyclin D1, CDK 4,
cyclin E and CDK 2 expression [46]. Similarly, another study also reported decreased expression levels
of cyclin D1, cyclin E, CDK2 and CDK4 in bladder cancer cells in a dose-dependent manner (0, 25,
50, 100 µg/mL) after 24 h of fucoidan treatment (undefined species source) [47]. Atashrazm et al. [48]
reported upregulated P21/WAF1/CIP1 expression and not cyclin D1 in APL cells treated for 24 h with
F. vesiculosus fucoidan. Other fucoidans have also been reported to affect cell cycle in a similar way.
Fucoidan from U. pinnatifida (commercially available or laboratory prepared) targeted p21Cip1/Waf
and E2F-1 in PC-3 cells [38] and cyclin D1 and CDK4 in mouse hepatoma Hca-F cells [49]. In line with
these studies, we showed that both crude fucoidans investigated led to cell cycle arrest in the G1 phase
of cell cycle. However, their severity and mechanisms were different. F. vesiculosus fucoidan caused the
cells to accumulate in the sub G1 phase of cell cycle, which is indicative of apoptotic population [50,51],
while the S. filipendula fucoidan caused only a slight shift of population from the G2 phase to the G1
phase of cell cycle with no significant accumulation in the sub-G1 phase, and this seemed to be due to
the MMW and HMW fractions of fucoidan within the crude extract.
3.2. F. vesiculosus Fucoidan Causes Stress-Induced Apoptosis-Like Cell Death in MG63 Cells
Preliminary experiments for this study (Supplementary Figure S2) showed a slight increase in
mitochondrial activity compared to control for doses below 100 µg/mL of F. vesiculosus fucoidan after
one day of treatment, despite no significant difference in DNA content (used here as a measure of
cell number), which strongly indicates that mitochondria may be more active in these cells than in
control cells. This is in line with the observation that apoptosis is an active process and requires more
ATP energy initially [52]. On Day three of culture however, JC-1 staining and TEM images confirmed
that mitochondria in these cells were significantly reduced in number. The remaining mitochondria
were dense, elongated and had a swollen cristae network, which may again indicate highly active
mitochondria and accumulation of ions in the intermembrane space [53–57]. There seemed to be
some mitochondria more swollen than the others and the cristae network seemed to be disintegrated
within the mitochondria into a dense matrix, which suggested that the inner mitochondrial membrane
may be intact. However, there may be damage to the outer mitochondrial membrane that eventually
led to the release of Cyt C from the intermembrane space into the cytosol, thereby triggering the
caspase cascade. This may have led to DNA fragmentation via endonuclease, seen via the TUNEL
assay [58] and TEM (chromatin marginalization and condensation), and finally, apoptosis-like cell
death, which was confirmed via Annexin V/PI staining. Some cells which may be more damaged
may have also undergone necrosis, which would explain the presence of debris and some ruptured
cells with damaged cell membranes or nuclear membranes [56,57]. Previously, similar mitochondrial
damage and chromatin condensation was found to be associated with increased accumulation of high
intracellular levels of ROS, depletion of glutathione, increased Bax-to-Bcl-2 ratio and activation of the
caspase cascade in human hepatocellular carcinoma SMMC-7721 cells after U. pinnatifida treatment [59].
Indeed, several studies (reviewed in Reference [60]) claim that fucoidans, mainly from F. vesiculosus
or U. pinnatifida, induce apoptosis via inhibition of phosphatidylinositol 3-kinase (PI3K)/Akt in human
acute promyelocytic leukaemia (APL) cells [48] and PC-3 prostate cancer cells [38], via inhibition of the
mitogen-activated protein kinase (MAPK) pathway in AML cells [48], MC3 human mucoepidermoid
carcinoma cells [61] and DU-145 Prostate Cancer Cells [62], via downregulation of ID-1 (expressed in
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actively proliferating cells) in hepatocellular carcinoma cells [63], via downregulation of β-catenin in
Eker rat leiomyoma tumour-derived cells [64] and PC-3 cells [38], and via generation of reactive oxygen
species (ROS) in 5637 human bladder cancer cells [65], human hepatocellular carcinoma SMMC-7721
cells [59] and MCF-7 breast cancer cells [22,66]. Recently, commercial fucoidan from U. pinnatifida
(average 130 kDa with 21% ± 3% fucose, 20% ± 5% galactose, 2% ± 2% mannose, and 30% ± 3%
sulphate) was also shown to induce apoptosis in MG63 osteosarcoma cells characterised by increased
roundness of the cells due to accumulation of F-actin at the cortex and increased expression of Annexin
V together with chromatin condensation [33].
It is strongly argued that authentic apoptosis only occurs in the body and is irrelevant to
non-renewable cell types, such as those used in vitro, as there is a lack of other cell types that play
an important role in apoptosis [67]. Hence, stress-induced apoptosis-like cell death (SIaLCD) is
often confused with apoptosis in most in vitro studies performed using cell lines [68–70]. Therefore,
we postulate that MG63 cells underwent SIaLCD and not apoptosis in the present study. One of
the targets of stress induction may have been in the ER, as TEM images also showed significant
ER-like swelling and formation of vesicles inside the cytosol of MG63 cells that positively correlated
to mitochondrial damage, all indicative of abnormal functioning of the ER and possible interplay
between ER and mitochondria in these cells [69]. To alleviate this stress, autophagy can be triggered
as a secondary response [71]. Recently, Hsu et al. [72] showed that both commercial fucoidans
from Laminaria japonica and F. vesiculosus prevented lung cancer cells via ROS-mediated induction,
Chen et al. [73] reported that commercial fucoidan from F. vesiculosus inhibited MDA-MB-231 breast
cancer cells and HCT116 colon cancer cells by increasing the expression of CHOP (related to ER-stress),
and Park et al. [74] reported that AGS human gastric adenocarcinoma cells had enhanced autophagy
and mitochondrial damage after treatment with commercial fucoidan (undefined source).
3.3. S. filipendula Fucoidan Causes Necrosis in MG63 Cells
TUNEL assay showed that only 11% of cells treated with 100 µg/mL S. filipendula fucoidan were
undergoing apoptosis-like death due to positive BrdU staining. On the other hand, the TEM images
revealed condensation and marginalisation of chromatin material in the nuclei (in almost all cells,
both intact or rupturing) complemented by damaged cell membranes, under the treatment of the same
fucoidan at the same dose. This suggests that the chromatin changes were mostly random and that
the mode of cell death in this case was most likely necrosis, oncosis or stress-induced necrosis-like
cell death (SInLCD) and not only SIaLCD [56,69,75]. In support of this postulate was the presence of
swollen mitochondria in these cells, wherein the cristae network was disorientated and marginalised
towards the edges of the mitochondrial membrane, leading to the appearance of gaps inside the
mitochondria. There were also some mitochondria that disintegrated within a dense matrix. All these
signs are suggestive of accumulation of inner membrane components and possible interference with
glycolysis, contributing to cell death. The fucoidan may also have affected other cell organelles such as
ER, where it may have interfered with Ca2+ dynamics [76] and protein folding, thus causing build-up
of misfolded or unfolded proteins inside ER. This stress may have again led to autophagy [77]. After
irreversible damage in the cell however, fucoidan may have led to cell death [69].
In another study, Costa et al. [9] treated HeLa cells with crude fucoidan from S. filipendula for
24 h and found increased Annexin V expression, and the authors suggest that the cells underwent
apoptosis via (glycogen synthase kinase-beta) GSK3β activation despite also reporting that there were
no changes in caspase 9, caspase 3, p53, NFκB, ERK or p38 expression. Activated GSK-3β interacts
with p53 to initiate the caspase cascade [78] and/or NFκB to activate the TNF signalling cascade [79,80]
in order to induce apoptosis [81]. Hence, we further suggest that S. filipendula fucoidan may have also
caused necrosis in those HeLa cells, similar as to that seen our present study.
We have shown, for the first time, variable localisation and penetration of two different types
of brown seaweed crude fucoidans. Though the exact mechanism of cellular uptake is unclear,
it is likely that structural variations in the two fucoidans may have led to variations in cell death
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mechanisms. Fucoidan from F. vesiculosus had twice as much sulphation as crude fucoidan from
S. filipendula. This may have led to a globular structure of F. vesiculosus fucoidan causing its aggregation
and clumping inside or around the cells and thus, exposing limited interaction sites to cellular
components such as scavenger receptor (SR-B1, SR-BII, CD36) [82,83] and reduced uptake by the cells.
This may have allowed for the cells to take their time and undergo SIaLCD [84]. On the other hand,
the S. filipendula fucoidan may have a more linear molecular conformation, exposing relatively more
reactive sites, which possibly also led to significantly more uptake of this fucoidan by the cells. As a
consequence, it may have interfered with more than one molecular mechanism inside the cell or even
led to irreparable DNA damage. Previously, extremely high ROS levels have been shown to cause
necrotic cell death [58,85].
3.4. Fucoidan Affects Cell Cytoskeleton Formation and Adhesion
Cell adhesion to ECM is essential for invasion and proliferation of cancer cells and our results
showed that all fucoidans from F. vesiculosus or S. filipendula inhibited MG63 cell attachment in a
dose-dependent manner via inhibition of vinculin expression and accumulation of F-actin in the
cell cortex (Figures 1 and 9). However, this effect was more severe in the case of F. vesiculosus
fucoidan. Previously, a similar mechanism of inhibition of attachment was observed for MDA-MB-231
adenocarcinoma cells after seeding in the presence of different doses of fucoidan from Ascophyllum
nodosum [41] and MG63 cells treated with 100 µg/mL of commercial U. pinnatifida fucoidan [66].
In another study, fucoidan from U. pinnatifida was also found to downregulate l-selectin (an adhesion
molecule) in Hca-F hepatocarcinoma cells [49].
3.5. HMW Fraction is Responsible for Cytotoxicity of Crude Fucoidan from S. filipendula
In this study, we consistently showed that greater inhibition of attachment, morphology,
proliferation and extracellular matrix formation by MG63 cells occurred at higher molecular weights
of S. filipendula fucoidan. These differences were clearly visible at lower doses and by 100 µg/mL,
MMW and HMW fractions induced cytotoxicity at a similar level. The TUNEL assay also revealed an
increase in dUTP-positive cells as the molecular weight of fucoidan increased. Furthermore, there was
significantly more mitochondrial membrane depolarisation for HMW-treated cells compared to LMW-
or MMW-treated cells. Interestingly, TEM images showed similar signs of toxicity as the crude fucoidan
extract from S. filipendula and there was evidence that the nucleolus of the cells treated with HMW and
MMW were fragmented, suggestive of these two fucoidans being more toxic. Altogether, these results
strongly indicated that all three molecular weight fractions may have similar effects on MG63 cells to
the crude fucoidan but fractions of >50 kDa were more severe than 10–50 kDa fractions. Moreover,
as more than 93% of the crude fucoidan extract from S. filipendula had molecular weight >50 kDa,
it seems that the MMW and HMW fractions defined the functionality of the crude extract.
Previously, the level and position of sulphation in fucoidan structure was considered to be an
important factor that determines the bioactivity of fucoidan [86]. Cho et al. [20] studied the anti-cancer
effects of 5–30 kDa and >30 kDa fractions of fucoidan from U. pinnatifida against the human stomach
cancer cell line AGS and found that over-sulphation significantly enhanced the inhibition of cell
growth for both molecular weight fractions. In this study, fucoidan from F. vesiculosus had the highest
sulphation degree of nearly 34%, followed by MMW, HMW, crude extract and then LMW fractions
of from S. filipendula. However, the degree of inhibition of MG63 attachment, viability, proliferation
and ECM formation was not always in the same order. Hence, sulphation levels may not be the only
determinant for the anti-cancer effect of fucoidans and there is likely to be a combinatorial effect of
sulphation level, molecular weight and cell penetration ability of the fucoidans.
4. Materials and Methods
All reagents were purchased from Sigma-Aldrich (Gillingham, UK) unless otherwise stated.
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4.1. Extraction and Purification of Fucoidan
Fucoidan from F. vesiculosus was sourced commercially (F5631, crude MWCO 20–200 kDa). S.
filipendula was collected in October 2017 (for crude extract) and in January 2018 (for molecular weight
fractions) in Santa Marta, Colombia (Otrosí number 5, Framework Contract for Access to Genetic
Resources and their Derived Products N◦ 126 of 2016, register number RGE0156-5). The collected
material was washed and dried at 50 ◦C in an oven for 6 h. The dried seaweed (DS) was coarsely
powdered in a coffee grinder. The isolation of the fucoidan was carried out according to the methodology
proposed by Synytsya et al. [87] with minor modifications. Sixty grams of the DS was added to 960 mL
of HCl 0.1M and allowed to stand at 4 ◦C for 24 h. The resulting filtrate was neutralized with 1 M NaOH
and precipitated with 3 volumes of ethanol. Then, the crude extract was obtained after centrifugation
for 30 min at 4500 RPM. The resulting precipitate was re-dissolved in water and the pH was adjusted to
2 with 1 M HCl. An aliquot of 4 M CaCl2 was added to remove the precipitate and the supernatant was
precipitated with 3 volumes of ethanol and re-dissolved in water. The enriched polysaccharide extract
was further purified by dialysis (MWCO 12–14 kDa) for 48 h at 4 ◦C. The enriched crude extract (385
mg) obtained was fractionated by ultracentrifugation using MWCO filters of 10, 50 and 100 kDa and 3
molecular weight fractions were obtained: low (10–50 kDa, LMW, 24.0 mg), medium (50–100 kDa,
MMW, 17.1 mg) and high (>100 kDa, HMW, 273.9 mg). Finally, the samples were lyophilized and
stored in the dark.
4.2. Measurement of Neutral Sugars in Fucoidan
Neutral sugars were measured using a phenol-sulfuric acid method [88]. Fifteen µL of each
fraction were added to 400 µL of deionized water. The standards of fucose, glucose and the samples
were mixed with 2 mL of sulfuric acid and mechanical stirring at 4000 RPM for 15 s. Subsequently,
400 µL of phenol (5%) was added and the resulting solution was heated at 90 ◦C for 5 min and cooled
in a water bath. The absorbance was measured at 480 and 490 nm for fucose and glucose, respectively.
The results were expressed based on the Equations (1) and (2) stated below:
% Neutral sugar (glucose) =
Asample − 0.0536
0.0309
∗ 400
V ∗ 10 ∗W (1)
% Neutral sugar ( f ucose) =
Asample − 0.0052
0.0057
∗ 400
V ∗ 10 ∗W (2)
where, Asample = absorbance of the sample at 490 nm, V = sample volume in µL and W = mass of the
sample to obtain 1 mg/mL.
4.3. Measurement of Acid Sugars in Fucoidan
Acid sugars were measured using a carbazole-sulfuric acid method [89]. Forty µL of each fraction
was added to 400 µL of deionized water. The samples and the standard d-glucuronic acid were mixed
with 2 mL of sodium tetraborate (0.95 g/L sulfuric acid) and samples were heated at 100 ◦C for 12 min.
Subsequently, 40 µL of carbazole (0.2% w/v, in ethanol) was added and heated at 100 ◦C for 10 min.
The absorbance was measured at 525 nm. The results were expressed in terms of hexuronic acid based
on Equation (3):
% Hexuronic acids =
Asample − 0.1388
0.0191
∗ 1
W
(3)
where, Asample = absorbance of the sample at 525 nm and W = mass of the sample to obtain 1 mg/mL.
4.4. Measurement of Sulphated Sugars Content
Fifty µL (1 mg/mL) of the fraction was mixed with 500 µL of deionized water. The samples and
the standard of chondroitin sulphate were mixed with 4 mL of the DMB solution (containing 11 mg
of 1,9DMB and 1 litre of sodium acetate 0.05 M, pH 4.75). The mixture was mechanically stirred
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at 4000 RPM for 15 s and left in the dark for 30 min. Absorbance was read at 520 nm [88,90]. The
quantification of sulphated sugars was determinate using Equation (4):
% Sulphated sugars =
Asample − 0.0275
0.0065
∗ 1
W
(4)
where, Asample = Absorbance of the sample at 520 nm and W = mass of the sample to obtain 1 mg/mL.
4.5. Culturing of MG63 Osteosarcoma Cells
MG63 osteosarcoma cells (passage 17 to 28) were maintained in α-MEM Eagle with sodium
bicarbonate, 10% Foetal Bovine Serum (LabTech, Heathfield, UK), 2 mM l-Glutamine and 100 mg/mL
Penicillin–Streptomycin at 37 ◦C and 5% CO2. At 90% confluence, cells were trypsinised, collected and
seeded at 10,000 cells/cm2 on ibiTreat µ-Slide 8 well, 24-well plates, 6-well plates, T12.5 or T25 with
working volumes of 250 µL, 500 µL, 2.5 mL, 2.5 mL and 5 mL, respectively. To assess cell attachment,
cells were seeded in the presence of different fucoidans as described below, and after 24 h, assessments
were performed. To assess proliferation or cell viability, treatments with different fucoidans were
applied 24 h after cell seeding.
4.6. Cell Metabolic Activity Assay
Metabolic activity was measured using PrestoBlue® assay (Thermofisher Scientific, Hemel
Hempstead, UK). At each time point, culture medium was removed and cells were washed with
phosphate buffer saline (PBS) before adding PrestoBlue® working solution (same volume as the culture
medium) prepared by mixing PrestoBlue® reagent with pre-warmed Hanks Balanced Salt Solution at a
ratio of 1:9 (v/v). Three wells containing only PrestoBlue® working solution with no cells were used as
blanks. During the kinetic phase of reactions, 100 µL aliquots per well were taken after gentle mixing
of cells and the fluorescence intensity was measured using 530 nm excitation and 590 nm emission
filters on an Infinite F200 PRO TECAN fluorescence microplate (Tecan, Theale, UK). Cell metabolic
activity was expressed after subtracting the reading for unreduced (blank) reagent and normalising to
the control (0 µg/mL fucoidan dose) for respective fucoidan.
4.7. Actin Cytoskeleton and Focal Adhesion Staining
Culture medium was removed, and cells were washed once with PBS, before fixing them with
3.7% paraformaldehyde in PBS for 15 min at RT. Vinculin and actin staining was performed using the
Actin Cytoskeleton and Focal Adhesion Staining Kit (Millipore, Watford, UK) as per the manufacturer’s
instructions. Briefly, cells were washed twice with wash buffer (0.05% Tween-20 in Dulbecco’s
Phosphate Buffered Saline (DPBS)) before permeabilizing with 0.1% Triton X-100 in DPBS for 5 min
and then again washing with wash buffer. Cells were then blocked for 30 min using 1% Bovine serum
albumin (BSA) in DPBS at RT, before adding anti-vinculin antibody (1:200 dilution) for 1 h at RT. Then,
cells were washed twice using wash buffer before incubating in GTxMS, FITC conjugated secondary
antibody (AP124F, Millipore, 1:100 dilution) and TRITC-labelled Phalloidin (P1951, Sigma, 1:1000
dilution) for 1 h at RT. Finally, cells were washed 2 times with wash buffer and counter stained with
10 µg/mL DAPI in DPBS for 5 min. Cells were visualised using a Nikon A1 Confocal microscope
with a 60× oil lens, keeping the imaging parameters constant for quantification. For quantification of
rounded cells, only actin and DAPI staining were performed and visualised using Eclipse Ti-E Nikon
fluorescence microscope at 10×.
4.8. DNA Content Assay
The culture medium was removed, and the cells were washed with PBS before adding sterile
deionised water (same volume as culture medium). Samples were lysed through three cycles of freeze
thawing at −80 ◦C and then scraped using a sterile pipette tip. Cell lysates were diluted 1 in 10 by
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adding 10 µL lysates to 90 µL buffer provided by the kit. The test lysates were loaded on to a flat
transparent 96-well plate (Grenier, Stonehouse, UK and DNA content was quantified using Quant-i™
PicoGreen® dsDNA Assay kit (Thermofisher Scientific, Hemel Hempstead, UK) according to the
manufacturer’s instructions. Briefly, 100 µL of PicoGreen working solution (1 in 200 dilution of dye
with Tris-EDTA buffer) was added to each test well and three blank wells containing only water. After
a 10 min incubation period at room temperature (RT), fluorescence intensity readings were taken on
an Infinite F200 PRO TECAN fluorescence microplate using 480 nm excitation and 520 nm emission
filters. The DNA concentration was extrapolated using a standard curve prepared from standard DNA
calf thymus provided with the assay kit. DNA content was expressed after subtracting the reading of
blank wells and normalising to the control (0 µg/mL fucoidan dose) for respective fucoidan.
4.9. Giemsa Staining
To assess cell morphology, cells were stained with Giemsa’s solution. It is a mixture of methylene
blue, eosin and Azure B and stains the nucleus dark blue and cytoplasm blue to pink. Culture medium
was removed, and cells were fixed with methanol for 10 s. Then, cells were washed with deionised
water to remove any residual methanol before immersing them in Giemsa stain for 15 min at RT.
Cells were then washed with deionised water to remove any residual stain and examined under a
MOTIC® AE 2000 inverted microscope at 40×.
4.10. Cell Cycle Analysis
Propidium iodide (PI) staining was performed to investigate cell cycle. Cells were seeded and left
overnight to attach. The next day, culture medium was changed to alpha-MEM without serum for
16 h to synchronise their cell cycle and then cells were treated with fucoidan. On day 3 of treatment,
medium was removed, and cells were washed twice with 1 mL of warm DPBS. After pelleting, 1 mL of
70% ethanol was added, and cells were vortexed immediately. Fixed cells were stored in a fridge until
staining. For PI staining, fixed cells were washed twice with DPBS and then 300 µL of PI working
solution (50 µg/mL PI in DPBS) and 50 µL of RNase working solution (0.3 µL/mL of RNase A in DPBS)
was added. Cells were incubated at 37 ◦C for 1 h and then left overnight at 4 ◦C. The next day, samples
were analysed using a BD LSRII flow cytometer and FlowJo software (BD, Wokingham, UK).
4.11. Annexin V/PI Staining
Annexin V/PI staining was performed to assess apoptosis or necrosis in cells. Cells were seeded
and left overnight to attach. The next day, fucoidan treatment was started. On day 3 of treatment,
Annexin V/PI staining was performed using the TACS® Annexin V-FITC Kit (Trevigen, Gaithersburg,
MD, USA). Briefly, the culture medium was collected in a tube, cells were washed with warm DPBS
before trypsinising and collecting them in the same tube. Samples were pelleted using 300 g for 5 min,
washed twice with DPBS and then stained with Annexin V and PI for 15 min at RT. The cells were
again pelleted and washed with binding buffer provided with the kit before running the samples in an
BD LSRII flow cytometer and analysing using FlowJo. For PI+ only and Annexin V+ only controls,
cells were treated with 1% Saponin and 30% H2O2 solution respectively, for 10 min. To exclude
autofluorescence signal, cells only (without any stain) were also included as a negative control group.
4.12. Transmission Electron Microscopy (TEM)
TEM was performed to examine the internal cell structure after fucoidan treatment. Cells were
seeded and the next day, treatment was started. After 3 days, cells were collected by trypsinisation,
washed with DPBS, pelleted and fixed in 2.5% glutaraldehyde/0.1 M PBS. Samples were subsequently
treated with 2% buffered Tannic acid and 2% Osmium tetroxide, dehydrated in graded ethanol solutions,
cleared in Epoxy Propane (EPP) and infiltrated in a 50/50 mix of EPP and araldite resin overnight on
a lab rotor. Infiltration was completed with two changes of pure araldite resin before samples were
embedded and polymerized for 72 hours at 60 ◦C. Ultrathin sections, approximately 85 nm thick, were
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cut on a Reichert Ultracet E ultramicrotome, picked up on copper EM grids and stained for 30 min
with 3% aq. Uranyl Acetate, washed in water and stained with Reynold’s Lead Citrate for 5 min.
Sections were examined on a FEI Tecnai Transmission Electron Microscope at an accelerating voltage
of 80 Kv. Electron micrographs were recorded using an Orius 1000B Gatan digital camera and Digital
Micrograph Software.
4.13. JC-1 Staining
The cyanine dye JC-1 (5,50,6,60-tetrachloro-1,10,3,30-tetraethylbenzimi- dazolylcarbocyanine
iodide) (T3168, ThermoFisher Scientific, Hemel Hempstead, UK) enables discrimination of polarised
and depolarised mitochondria. Normally JC-1 forms red fluorescent J-aggregates when concentrated in
polarised mitochondria in response to their higher membrane potential. However, upon depolarisation
of the mitochondrial membrane, JC-1 forms green monomers [91]. MG63 cells were seeded and left
overnight to attach. The next day, treatment with fucoidan was started. On day 3 of treatment, culture
medium was removed and cells were washed for 5 min with warm DPBS before incubating them in
10 µM of JC-1 dye in culture medium for 30 min. Dye was removed and cells were again washed with
DPBS and visualised under ZEISS LSM 880 with Airyscan with a Plan-Apochromat 40×/1.3 oil lens
using excitation at 488 nm and emission at 496–455 nm (for green monomers) and 576–719 nm (for red
aggregates), keeping the imaging parameters constant for quantification.
4.14. Immunostaining for Cytochrome C (Cyt C) and Fucoidan
Culture medium was removed and cells were washed once with PBS, before fixing them with
3.7% paraformaldehyde in PBS for 10 min at RT. Samples were permeabilised with 0.1% Triton X-100
in DPBS for 1 h, then washed two times for 5 min with DPBS before blocking with 3% goat serum in
1% BSA/DPBS for 30 min. After removing the blocking solution, the samples were incubated overnight
at 4 ◦C with BAM 3 (Hybridoma extracts containing anti-fucoidan primary antibody, 1:10 dilution) [92]
or 1 µg/mL of anti-cyt c primary antibody (ab13575, Abcam, Cambridge, UK,) in blocking solution.
The next day, samples were washed twice in DPBS for 5 min and then incubated with 1 µg/mL of Alexa
Fluor 674 (red) goat anti-rat IgG preabsorbed (ab150167, Abcam) in blocking solution for 2 h at RT.
Cells were again washed twice in DPBS for 5 min and counter stained with 100 nM of Acti-stain 488
phalloidin (PHDG1-A, Cytoskeleton, Inc., Denver, CO, USA) (if needed) and 10 µg/mL DAPI in 1%
BSA/DPBS for 15 min at RT. Finally, cells were washed with DPBS and visualised using a Nikon A1
Confocal microscope with a 60× oil lens, keeping the imaging parameters constant for quantification.
Cells with no primary or secondary antibody staining were used to exclude auto-fluorescence and
controls with primary Ab only and secondary Ab only were also used to exclude non-specific Ab
staining. Image analysis was performed using Image J Version: 2.0.0-rc-69/1.52p.
4.15. Terminal Deoxynucleotidyl Transferase dUTP Nick End Labelling (TUNEL) Assay
A TUNEL assay was performed to investigate DNA fragmentation in the latest stage of apoptosis.
Cells were seeded and left overnight to attach. The next day, fucoidan treatment was started. On day 3
of treatment, a Guava TUNEL Assay kit (4500-0121, Millipore) was used to perform the assay. Culture
medium was removed, and cells were washed with warm DPBS before trypsinising and collecting in
sterile tubes. The cells were then pelleted by centrifuging at 300 g for 5 min and washed again with
DPBS before fixing them with 3.7% paraformaldehyde in PBS for 20 min. Cells were stored at 4 ◦C in
DPBS until staining. The TUNEL assay was performed as per the manufacturer’s instructions. Briefly,
DPBS was removed from fixed cells, 70% ethanol (ice cold) was added and samples were stored in
–20 ◦C for 2 h and then washed twice with wash buffer before adding the DNA labelling mix for 1 h at
37 ◦C. After this, rinsing buffer was added to the mix and cells were again pelleted. Supernatant was
removed and cells were again incubated in anti-BrdU (TRITC-labelled) staining mix for 30 min at RT in
the dark. Finally, rinsing buffer was added to the cells and analysed using a BD LSRII flow cytometer
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and FlowJo software. Positive and negative controls provided with the kit were used to select TRITC−
and TRITC+ cells.
4.16. Statistical Analysis
All statistical analyses were performed using IBM SPSS Statistics 22. Mean and standard deviation
were computed for at least three replicate samples in all experiments, except JC-1 stained images, where
2 fields of view were used and 10–15 cells per condition were assessed. For comparisons, one-way or
two-way analysis of variance (ANOVA) was performed. Fucoidan type and concentration were two
fixed factors. For pairwise comparisons, post-hoc analyses using Least Significant Difference (LSD),
equivalent to no adjustments, were carried out. P values < 0.05 were considered significant. * indicates
p < 0.05 for pairwise comparisons between groups shown, # indicates p < 0.05 relative to respective
vehicle controls (0 µg/mL).
5. Conclusions
Our findings here showed that MG63 osteosarcoma cells are inhibited by fucoidans from two
different brown algae, however the mechanism of action varies based on the penetrability of the
fucoidan inside the cell. Moreover, as the molecular weight of fucoidan increases, its toxic effect also
increases. Fucoidan from S. filipendula from the Colombian coast was, for the first time, investigated
for a biomedical application, and this study provides evidence for its potential for anti-cancer therapy.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/18/2/104/s1,
Figure S1: Assessment of MG63 cell morphology by actin staining, Figure S2: Toxicity of crude fucoidan derived
from F. vesiculosus on MG63 cells after 1 day of treatment. Figure S3: Cell cycle analysis on Day 2 of treatment
with 100 ug/mL of S. filipendula fucoidans (crude, LMW, MMW and HMW). Figure S4: Mean ± SD of viable,
early apoptotic, late apoptotic and dead MG63 cells as seen through Annexin V/PI staining on day 3 of treatment
with different fucoidans.
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